2026-525484-40-00招募中1 期
A Phase 1 Study of PRT12396 in Participants with Select Myeloproliferative Neoplasms
Prelude Therapeutics Inc.16 个研究点 分布在 3 个国家目标入组 22 人开始时间: 2026年8月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 22
- 试验地点
- 16
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Medical Lead
Scientific
Prelude Therapeutics Inc.
研究点 (16)
Loading locations...
相似试验
招募中
1 期
A Phase 1 Study of PRT3789 in Participants with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutationgastroesophageal junctionSkin Cancer/MelanomaLung Adenocarcinomanon-small cell lung cancer (NSCLC)Esophageal/gastric cancerColon adenocarcinomaUterine/Endometrioid AdenocarcinomaHead and Neck Squamous cell Carcinomagastrointestinal cancerBreast CancerOvarian CancerPancreatic CancerBladder cancerLung Squamous cell carcinoma2022-502850-14-00Prelude Therapeutics Inc.70
招募中
1 期
A Phase 1 Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib or Venetoclax in Participants with Relapsed/Refractory Hematologic MalignanciesRichter's SyndromeChronic Lymphocytic Leukemia (CLL)Mantle Cell Lymphoma (MCL)Acute myeloid leukemia (AML)Marginal zone lymphoma (MZL)T-cell lymphoma (TCL) subtypesMyelodysplastic syndrome (MDS)MDS/myeloproliferative neoplasm (MPN) overlap syndromeChronic myelomonocytic leukemia (CMML)Small Lymphocytic Lymphoma (SLL)Aggressive B-Cell Non-Hodgkin's Lymphoma2022-502672-23-00Prelude Therapeutics Inc.109
尚未招募
3 期
A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering TherapyNon-familial Hypercholesterolemia and Mixed HyperlipidemiaNCT07421284CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.900
尚未招募
Phase 3 4
A clinical study to evaluate the the Anabolic Efficacy of PRP-02 in Healthy Human Adults.Normal Hematological and Biochemical ParametersCTRI/2024/06/068758Amway Global Services India (AGSI)30
已完成
2 期
A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed HyperlipidemiaHypercholesterolemia and Mixed HyperlipidemiaNCT07421232CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.156